Theseus Therapies uses a small‑molecule discovery platform that integrates structure‑based design, high‑throughput phenotypic screening, and biomarker‑guided validation to create CNS‑penetrant compounds targeting protein aggregation, kinase signaling, and mitochondrial dysfunction in Alzheimer’s and Parkinson’s disease. The company advances candidates through adaptive Phase I/II trials with pharmacodynamic biomarkers and offers co‑development partnerships to pharmaceutical and biotech companies.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease lack therapies that alter the underlying disease trajectory; existing treatments are largely symptomatic and do not prevent neuronal loss. This creates a substantial clinical and economic burden as patients experience progressive decline despite current care options.
Solution
Theseus Therapies applies a small‑molecule drug discovery platform that targets pathogenic mechanisms driving neurodegeneration. By integrating structure‑based design, high‑throughput phenotypic screening, and biomarker‑guided validation, the company identifies compounds that can restore neuronal function and slow disease progression. Lead programs focus on modulating protein aggregation, kinase signaling, and mitochondrial dysfunction in Alzheimer’s and Parkinson’s disease models. Optimized blood‑brain barrier permeability and target engagement are confirmed through in vitro human iPSC‑derived neuron assays and translational animal studies. The pipeline advances candidates through adaptive clinical trial designs that incorporate pharmacodynamic biomarkers to de‑risk late‑stage development. This approach aims to deliver disease‑modifying therapeutics that can be co‑developed with pharmaceutical partners or advanced to market independently.
Target Audience
Primary customers are pharmaceutical companies and biotech partners seeking co‑development opportunities for disease‑modifying neurodegenerative therapies, as well as academic research consortia focused on translational neuroscience.
Features
- Proprietary library of CNS‑penetrant small molecules targeting protein aggregation, kinase pathways, and mitochondrial homeostasis
- Structure‑based virtual screening combined with high‑content phenotypic assays in human iPSC‑derived neuronal cultures
- Integrated PK/PD modeling to predict brain exposure and target occupancy across species
- Biomarker‑driven patient stratification using CSF tau, α‑synuclein, and neurofilament light chain assays
- Adaptive Phase I/II trial architecture with interim futility analyses and seamless escalation to Phase III
- Scalable GMP synthesis platform enabling rapid up‑scaling of lead candidates
- Robust safety pharmacology package including off‑target profiling and neurotoxicity assessment